Loading…
Vivani Medical, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in VANI.
▼ -84.9% over 5Y.
today you would have $129.57▼ -87.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.23 | $1.16 | $1.02 | $0.85 | $4.89 | $5.61 | $17.81 | $21.26 | $45.84 | $47.28 | $141.36 | $246.24 | |
| P/S | 19.8x | — | — | — | — | — | — | 27.5x | 16.0x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MXCTMaxcyte Inc | $1.24 | — | 0.8x | — | -20.39% | $127.98M |
| VTVTvTv Therapeutics Inc. | $32.36 | — | 5.1x | — | -15.80% | $127.95M |
| BDTXBlack Diamond Therapeutics, Inc. | $2.23 | — | 1.3x | — | -37.22% | $127.78M |
| TLSATiziana Life Sciences Ltd | $1.01 |
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
Company description provided by Yahoo Finance.
| 14.4x |
| 27.8x |
| 23.7x |
| 0.1x |
| P/B | 10.2x | 6.6x | 3.9x | 2.7x | 1.0x | 26.1x | 22.3x | 12.8x | 35.7x | 14.5x | 10.0x | 10.5x | 0.0x |
| EPS | -$0.43 | -$0.43 | -$0.50 | — | -$0.81 | -$2.16 | -$6.84 | -$12.69 | -$12.72 | -$20.16 | -$13.44 | -$33.84 |
| Profit margin | -669.19% | — | — | — | — | — | — | -994.14% | -508.90% | -358.06% | -829.48% | -223.66% | -1035.32% |
| ROE | -233.39% | -169.16% | -133.37% | -123.56% | -31.35% | -518.17% | -763.08% | -461.75% | -1137.94% | -361.79% | -297.62% | -98.79% | -101.68% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -924.32% |
| $128.53M |
| CPIXCumberland Pharmaceuticals Inc | $8.46 | — | 7.3x | — | -14.39% | $126.76M |
| HCATHealth Catalyst, Inc. | $1.72 | — | 1.3x | — | -118.12% | $129.44M |